Evidence map›Paper›PMID 32537547›Full record

ArticleJBMR plus2020

Aaliyah Riccardi, Carolina Lemos, Ryan Ramos, Justin Bellizzi, Kourosh Parham, Taylor C Brown, Reju Korah, Tobias Carling, Jessica Costa-Guda, Andrew Arnold

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Biosensors for Point Mutation Detection.Frontiers in bioengineering and biotechnology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Aaliyah RiccardiCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.
Carolina LemosCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.
Ryan RamosCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.
Justin BellizziCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.
Kourosh ParhamDivision of Otolaryngology University of Connecticut School of Medicine Farmington CT USA.
Taylor C BrownYale Endocrine Neoplasia Laboratory, Department of Surgery Yale School of Medicine New Haven CT USA.
Reju KorahYale Endocrine Neoplasia Laboratory, Department of Surgery Yale School of Medicine New Haven CT USA.
Tobias CarlingYale Endocrine Neoplasia Laboratory, Department of Surgery Yale School of Medicine New Haven CT USA.
Jessica Costa-GudaCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.ORCID https://orcid.org/0000-0001-6437-1693
Andrew ArnoldCenter for Molecular Oncology University of Connecticut School of Medicine Farmington CT USA.
University of Connecticut · USYale University · USWashington University in St. Louis · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Benign parathyroid adenoma is the most common cause of primary hyperparathyroidism, whereas malignant parathyroid carcinoma is exceedingly rare. Distinguishing parathyroid carcinoma from benign adenoma is often difficult, and may be considerably delayed even after surgical resection until the rigorous diagnostic criteria of local invasion of surrounding tissues and/or distant metastases are fulfilled. Thus, new insights into their respective molecular bases may potentially aid in earlier diagnostic discrimination between the two, as well as informing new directions for treatment. In two recent studies, gain-of-function mutations in

Indexed as

CANCERDISORDERS OF CALCIUM/PHOSPHATE METABOLISMPARATHYROID‐RELATED DISORDERS

Identifiers

PMID32537547
PMCPMC7285753
OpenAlexW3012908944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.